Literature DB >> 24651664

Target lesion selection: an important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1.

Sebastian Keil1, Alexandra Barabasch, Timm Dirrichs, Philipp Bruners, Nienke Lynn Hansen, Heribert B Bieling, Tim H Brümmendorf, Christiane K Kuhl.   

Abstract

PURPOSE: We conducted a systematic analysis of factors (manual vs automated and unidimensional vs 3-dimensional size assessment, and impact of different target lesion selection) contributing to variability of response categorization in the Response Evaluation Criteria for Solid Tumors 1.1. PATIENTS AND METHODS: A total of 41 female patients (58.1 ± 13.2 years old) with metastatic breast cancer underwent contrast-enhanced thoracoabdominal computed tomography for initial staging and first follow-up after systemic chemotherapy. Data were independently interpreted by 3 radiologists with 5 to 9 years of experience. In addition, response was evaluated by a computer-assisted diagnosis system that allowed automated unidimensional and 3-dimensional assessment of target lesions.
RESULTS: Overall, between-reader agreement was moderate (κ = 0.53), with diverging response classification observed in 19 of 41 patients (46%). In 25 patients, readers had chosen the same, and in 16, readers had chosen different target lesions. Selection of the same target lesions was associated with a 76% rate of agreement (19/25) with regard to response classification; selection of different target lesions was associated with an 81% rate of disagreement (13/16) (P < 0.001). After dichotomizing response classes according to their therapeutic implication in progressive versus nonprogressive, disagreement was observed in 11 of 41 patients (27%) (κ = 0.57). In 9 of these 11 patients, readers had chosen different target lesions. Disagreement rates due to manual versus automated or unidimensional versus volumetric size measurements were less important (11/41 and 6/41; 27% and 15%, respectively).
CONCLUSIONS: A major source of variability is not the manual or unidimensional measurement, but the variable choice of target lesions between readers. Computer-assisted diagnosis-based analysis or tumor volumetry can help avoid variability due to manual or unidimensional measurements only but will not solve the problem of target lesion selection.

Entities:  

Mesh:

Year:  2014        PMID: 24651664     DOI: 10.1097/RLI.0000000000000048

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  9 in total

1.  Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability.

Authors:  Joo Hyun O; Heather Jacene; Brandon Luber; Hao Wang; Minh-Huy Huynh; Jeffrey P Leal; Richard L Wahl
Journal:  J Nucl Med       Date:  2017-03-30       Impact factor: 10.057

2.  Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients.

Authors:  Di Wu; Liangfa Xiong
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

3.  Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.

Authors:  S A Hayes; M C Pietanza; D O'Driscoll; J Zheng; C S Moskowitz; M G Kris; M S Ginsberg
Journal:  Eur J Radiol       Date:  2016-01-02       Impact factor: 3.528

4.  Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.

Authors:  Hubert Beaumont; Tracey L Evans; Catherine Klifa; Ali Guermazi; Sae Rom Hong; Mustapha Chadjaa; Zsuzsanna Monostori
Journal:  Cancer Imaging       Date:  2018-12-11       Impact factor: 3.909

5.  Prognostic evaluation of resectable colorectal cancer using platelet-associated indicators.

Authors:  Weihua Qian; Xin-Xin Ge; Jing Wu; Fei-Ran Gong; Meng-Yao Wu; Meng-Dan Xu; Lian Lian; Wen-Jie Wang; Wei Li; Min Tao
Journal:  Oncol Lett       Date:  2019-05-21       Impact factor: 2.967

Review 6.  RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?

Authors:  Antoine Iannessi; Hubert Beaumont; Yan Liu; Anne-Sophie Bertrand
Journal:  Insights Imaging       Date:  2021-03-18

7.  Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.

Authors:  Laure Fournier; Lioe-Fee de Geus-Oei; Daniele Regge; Daniela-Elena Oprea-Lager; Melvin D'Anastasi; Luc Bidaut; Tobias Bäuerle; Egesta Lopci; Giovanni Cappello; Frederic Lecouvet; Marius Mayerhoefer; Wolfgang G Kunz; Joost J C Verhoeff; Damiano Caruso; Marion Smits; Ralf-Thorsten Hoffmann; Sofia Gourtsoyianni; Regina Beets-Tan; Emanuele Neri; Nandita M deSouza; Christophe M Deroose; Caroline Caramella
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

8.  Volumetric measurements of target lesions: does it improve inter-reader variability for oncological response assessment according to RECIST 1.1 guidelines compared to standard unidimensional measurements?

Authors:  Markus Zimmermann; Christiane Kuhl; Hanna Engelke; Gerhard Bettermann; Sebastian Keil
Journal:  Pol J Radiol       Date:  2021-10-22

9.  iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison.

Authors:  Laura Schomburg; Amer Malouhi; Marc-Oliver Grimm; Maja Ingwersen; Susan Foller; Katharina Leucht; Ulf Teichgräber
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-14       Impact factor: 4.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.